Drugs.com - Clinical Trials

News of Plaque-Clearing Drug Tops Week of Major Advances Against Alzheimer's Disease

Fri, 10 Feb 2012 14:45:54 GMT

Clarksburg, MD, February 9, 2012—“In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer’s disease,” said Stacy Pagos Haller, President and CEO of the American Health...

Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis

Fri, 10 Feb 2012 12:21:01 GMT

Clinical Trial Supported by $510,000 Grant from the National Cancer Institute PRINCETON, N.J., Feb. 10, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced...

Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network (LDN) World Symposium

Thu, 09 Feb 2012 21:36:49 GMT

- SBC-102 was well tolerated and demonstrated predicted pharmacodynamic effects in a Phase I/II trial in late onset LAL Deficiency - LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 9, 2012 - Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a...

Gene Therapy for Inherited Blindness Succeeds in Patients' Other Eye

Thu, 09 Feb 2012 16:02:47 GMT

-- In 3 Adults, Repeat Dose Safely Improves Vision -- A Joint News Release from The Children's Hospital of Philadelphia and the University of Pennsylvania PHILADELPHIA, Feb. 9, 2012 /PRNewswire-USNewswire/ -- Gene therapy for congenital...

Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

Thu, 09 Feb 2012 14:02:48 GMT

- Data highlights novel immunomodulatory effects of entinostat - WALTHAM, Mass., Feb. 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer...

ACTT 'Allergy Drops' - Needle Free Allergy Treatment

Thu, 09 Feb 2012 12:02:01 GMT

Narrowing the gap between human and veterinary medicine. AUSTIN, Texas, Feb. 9, 2012 /PRNewswire/ -- Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy as an alternative method for administering...

Conclusive Results of Regulatory Toxicology Studies With Gft505

Wed, 08 Feb 2012 19:30:14 GMT

?? The complete regulatory toxicology package of GFT505 confirms its safety in long-term treatment. ? Lille (France), Cambridge (Massachusetts, United States), February 8th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a...

Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half

Wed, 08 Feb 2012 16:02:52 GMT

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is growing evidence that supports an association between atypical fractures of the femur – a rare break of the thigh bone, typically without trauma – and the use of...

Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints

Wed, 08 Feb 2012 16:02:23 GMT

Phase 3 Studies of Eliglustat Tartrate Fully Enrolled CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today four-year follow-up data from patients enrolled in the phase 2...

Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain

Wed, 08 Feb 2012 16:02:21 GMT

Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc....

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder

Wed, 08 Feb 2012 13:02:42 GMT

NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 - Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational...

Pivotal Study Published in JAMA Confirms Potential of Novartis Candidate Vaccine Bexsero to Help Protect Infants Against Devastating Meningococcal Serogroup B Disease

Wed, 08 Feb 2012 12:02:55 GMT

Data previously presented at ESPID annual meeting add to the body of evidence showing that Bexsero can help protect all vulnerable age groups Study including more than 1,800 infants showed Bexsero induces robust immune...

Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial

Tue, 07 Feb 2012 23:02:17 GMT

SEATTLE, Feb. 7, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which...

Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms

Tue, 07 Feb 2012 22:02:08 GMT

-- JX-594 Selectivity is Multi-Mechanistic, Driven by Genetic Traits Common in Solid Tumors -- SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and...

Cannabis Science Awaits Full Biopsy Report As Newest Series of Photos Shows Cancer Lesion Evidently Completely Killed & Hair Re-growth Begins On New Healthy Skin From 2nd Self-Administering Cancer Patient

Tue, 07 Feb 2012 19:02:30 GMT

DENVER--(BUSINESS WIRE)--Feb 7, 2012 - Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the...

Thrasos and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease

Tue, 07 Feb 2012 18:02:29 GMT

Preclinical Research Validates Role of BMP Pathway in Treating Progressive Kidney Disease and Potential for Thrasos' Compounds to Selectively Target the Pathway MONTREAL--(BUSINESS WIRE)--Feb 7, 2012 - Thrasos today announced that the journal...

Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status

Tue, 07 Feb 2012 18:02:04 GMT

PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Anacor Pharmaceuticals (NASDAQ:ANAC) announced today positive preliminary results from two safety studies of AN2728 - a maximal use systemic exposure (MUSE) study in psoriatic patients and a...

New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia

Tue, 07 Feb 2012 16:02:09 GMT

Phase III study met primary endpoint INDIANAPOLIS, Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and tamsulosin...

Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar

Tue, 07 Feb 2012 13:02:36 GMT

Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 7, 2012 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line...

Clinical Results from Aduro's Phase 1 Trials Published in Clinical Cancer Research

Tue, 07 Feb 2012 11:02:18 GMT

BERKELEY, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research (volume 18(3), pages 1-11). In the article, which was...

Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)

Mon, 06 Feb 2012 20:02:57 GMT

Aim to File for Approval of Lubiprostone as First Oral Drug for Prescription-based Treatment of OBD Anticipate sNDA Filing in US in First Half of 2012 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A.,...

NEJM features two positive pivotal trials of HRA Pharma compound ulipristal acetate for the treatment of uterine fibroids

Mon, 06 Feb 2012 20:02:34 GMT

Paris, February 2, 2012 - The New England Journal of Medicine (NEJM) today published results of two phase III clinical trials introducing ulipristal acetate, HRA Pharma proprietary compound, as an effective pre-operative treatment of...

Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting

Mon, 06 Feb 2012 19:02:54 GMT

QUÉBEC CITY, Feb. 3, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:?AEZ) (the "Company") today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate...

Combined Asthma Medication Therapy Shown to Reduce Attacks

Mon, 06 Feb 2012 18:02:44 GMT

DETROIT, Feb. 6, 2012 – A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks. Researchers say using long-acting beta-agonists (LABAs) in fixed-dose combination...

Novel Drug Shows Significant Promise in Treating Severe Stroke Patients

Mon, 06 Feb 2012 17:02:22 GMT

Remedy Pharmaceutical's drug may finally hold the answer to solving this medical dilemma NEW YORK--(BUSINESS WIRE)--Feb 6, 2012 - Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little....

Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis(TM) Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Mon, 06 Feb 2012 12:02:09 GMT

-Results Support Planned, Randomized Phase 3 ADAPT Study- DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis immunotherapy, AGS-003, in...

Study Finds No Drug-Drug Interaction Between Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI

Fri, 03 Feb 2012 17:02:33 GMT

RIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the...

High Triglyceride Levels Found to Predict Stroke in Older Women

Fri, 03 Feb 2012 14:02:47 GMT

A Stronger Link than Cholesterol Levels to Ischemic Stroke BRONX, N.Y., Feb. 2, 2012 /PRNewswire-USNewswire/ -- In a surprising finding with significant implications for older women, researchers at Albert Einstein College of Medicine of...

Young Children Exposed to Anesthesia Multiple Times Show Elevated Rates of ADHD

Fri, 03 Feb 2012 14:02:23 GMT

ROCHESTER, Minn.--(BUSINESS WIRE)--Feb 2, 2012 - Mayo Clinic researchers have found that multiple exposures to anesthesia at a young age are associated with higher rates of attention-deficit/hyperactivity disorder (ADHD). VIDEO ALERT:...

Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC

Fri, 03 Feb 2012 13:02:55 GMT

SAN DIEGO, Feb. 3, 2012 /PRNewswire/ -- Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse...

Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting

Fri, 03 Feb 2012 13:02:53 GMT

QUÉBEC CITY, Feb. 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate...

Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic Stroke

Fri, 03 Feb 2012 12:02:53 GMT

First ever data to demonstrate improvement in motor function following stroke with oral drug treatment initiated several weeks after event HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 3, 2012 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented...

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma

Fri, 03 Feb 2012 11:02:22 GMT

14.7 months median progression free survival 28% confirmed partial response rate & 72% disease control rate at week 16 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today reported preliminary data from a cohort...

Diamyd Medical's Phase III Study Published in The New England Journal of Medicine

Thu, 02 Feb 2012 20:34:04 GMT

STOCKHOLM--(BUSINESS WIRE)--Feb 2, 2012 - Regulatory News: An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England...

Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)

Thu, 02 Feb 2012 20:02:21 GMT

Aim to File for Approval of Lubiprostone as First Oral Drug for Prescription-based Treatment of OBD Anticipate sNDA Filing in US in First Half of 2012 BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Feb 2, 2012 - Sucampo Pharmaceuticals, Inc....

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy

Thu, 02 Feb 2012 20:02:16 GMT

Expression levels of CGEN-15001T on various solid, hematological cancer cells and immune cells combined with its immunomodulatory activities support its potential use as a powerful drug target for cancer immunotherapy TEL AVIV, Israel--(BUSINESS...

International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients with Severe Hemophilia B

Thu, 02 Feb 2012 19:02:13 GMT

Results from the Phase I of the PROLONG-9FP trial program demonstrate clinical safety and improved pharmacokinetics of rIX-FP compared to current treatment options St. Gallen, Switzerland — 02 February 2012 CSL Behring today announced the...

Cannabis Science Reports Success For 4th Brand New Self-Administering Cancer Patient

Thu, 02 Feb 2012 16:02:42 GMT

DENVER--(BUSINESS WIRE)--Feb 2, 2012 - Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell...

International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients With Severe Hemophilia B

Thu, 02 Feb 2012 14:02:23 GMT

Results from the Phase I of the PROLONG-9FP trial program demonstrate clinical safety and improved pharmacokinetics of rIX-FP compared to current treatment options ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire/ -- CSL Behring today announced...

Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer

Thu, 02 Feb 2012 13:02:27 GMT

OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427 in Combination with Zytiga® (abiraterone) in Castrate-Resistant Prostate Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 2, 2012 /CNW/ - OncoGenex Pharmaceuticals,...